TRPX - Therapix Biosciences Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.42
+0.07 (+1.53%)
As of 9:46AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.35
Open4.42
Bid4.40 x 1100
Ask4.46 x 1000
Day's Range4.38 - 4.42
52 Week Range3.84 - 7.69
Volume1,161
Avg. Volume126,784
Market Cap15.823M
Beta-0.13
PE Ratio (TTM)N/A
EPS (TTM)-1.76
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
    PR Newswire9 days ago

    Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome

    TEL AVIV, Israel, June 11, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announces sponsorship of the 11th  European Society for the Study of Tourette Syndrome (ESSTS) conference, in Copenhagen Denmark, on June 13th until June 15th, as part of the Company's strategy to develop therapy for Tourette's patients and to support the Tourette's community.

  • Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug
    PR Newswire15 days ago

    Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug

    TEL AVIV, Israel, June 5, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that on June 05, 2018, the first subject was enrolled for its Phase IIa, sponsor-initiated clinical trial using the Company's cannabinoid-based technology THX-110 for Obstructive Sleep Apnea (OSA), at Assuta Medical Center, the largest private hospital network in Israel.

  • Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
    PR Newswire20 days ago

    Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update

    TEL AVIV, Israel , May 31, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX)  a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, ...

  • PR Newswirelast month

    Therapix Biosciences Issues CEO's Letter to Shareholders

    TEL AVIV, Israel, May 15, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, issued today a letter to its shareholders, from the CEO and chairman of the company. "Therapix Biosciences has experienced an encouraging and optimistic start to 2018. All of these activities led to Q2 2018 being an important inflection point in our Company's development as we hope to see the fruits of these efforts in our product pipelines in each of our focus areas in drug development.

  • Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange
    PR Newswirelast month

    Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange

    TEL AVIV, Israel, May 9, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (TASE: THXBY) ("Therapix" or "the Company"), a biopharmaceutical company focused on discovering, ...

  • InMed Announces Appointment of Joshua Blacher as Chief Business Officer
    CNW Group2 months ago

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

    InMed Announces Appointment of Joshua Blacher as Chief Business Officer

  • ACCESSWIRE2 months ago

    Blog Exposure - Therapix Reported Positive Top-line Results of Phase-IIa Study for Tourette Syndrome Treatment

    Stock Monitor: Madrigal Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Therapix Biosciences Ltd (NASDAQ: TRPX ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Teva and Therapix

    NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Shares of Therapix were popping on Monday after positive trial results about the company's proprietary cannabinoid product platform THX-IIO fell upon the eyes ...

  • MarketWatch2 months ago

    Therapix shares surge 30% premarket on news of positive trial of Tourette syndrome treatment

    Therapix Biosciences Ltd. shares soared more than 30% in premarket trade Monday, after the company reported positive results in a trial of a treatment for Tourette syndrome. The company said a phase IIa ...

  • Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
    PR Newswire2 months ago

    Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program

    "The successful completion of this study is a key milestone in our clinical development plan of our proprietary drug candidate THX-110 for the treatment of Tourette syndrome for which current available treatments are frequently inadequate or unsafe," said Adi Zuloff-Shani, Ph.D, Chief Technology Officer at Therapix. The study was a single-arm, open-label trial, in which each subject both received one daily treatment of the drug via oral administration and was followed-up for a period of 12 weeks.

  • Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
    PR Newswire3 months ago

    Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain

    TEL AVIV, Israel, March 20, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) for THX-110 in the treatment of Chronic Low Back Pain. Therapix expects to commence a Phase IIa clinical trial in the second quarter of 2018. "We believe that the clearance of this IND by the FDA is a significant milestone for Therapix and for its platform technology THX-110 and for patients suffering from chronic low back pain for whom existing medicines often do not provide adequate relief," stated Adi Zuloff-Shani, Ph.D, Therapix's Chief Technology Officer.

  • Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
    PR Newswire4 months ago

    Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

    TEL AVIV, Israel, Feb. 7, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that it has held a pre-Investigational New Drug (pre-IND) communication with the U.S. Food and Drug Administration (FDA) to discuss the regulatory pathway for the development of THX-110 for the treatment of Tourette Syndrome. "Following this informative communication with the FDA, we can confirm that the IND for THX-110 will not require any additional nonclinical data to support a phase IIb study in the the United States.

  • Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018
    PR Newswire5 months ago

    Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018

    TEL AVIV, Israel, Jan. 9, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, is expanding into precision medicine through a new fully-owned subsidiary in order to develop novel solutions for pain. This new subsidiary will complement the Company's cannabinoid-based drug development strategy.

  • Reuters7 months ago

    Therapix expects to have results of Tourette's drug trial by end of Q1

    Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues. It has completed enrolment of 16 patients for its Phase IIa study at Yale University, where it will assess the drug that combines a synthetic cannabinoid already approved by the U.S. Food and Drug Administration with a fatty acid derivative called palmitoylethanolamide (PEA). Therapix believes PEA may increase the efficacy of the cannabinoid while lowering the required dosage and reducing adverse effects.

  • Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
    PR Newswire7 months ago

    Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

    TEL AVIV, Israel, Dec. 4, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based therapies, announces the completion of enrollment in its investigator-initiated Phase IIa study at Yale University evaluating its investigational compound THX-110, a therapeutic compound consisting of FDA-approved dronabinol (synthetic ∆-9-tetrahydracannabinol) and palmitoylethanolamide (PEA) , for Tourette syndrome. "We're optimistic that this study will support earlier clinical research documenting the therapeutic benefits of cannabinoid-based therapies and may suggest that the combination of dronabinol and PEA, which we are developing as our investigatory compound THX-110, will demonstrate a safe and efficacious treatment for this highly debilitating disease with high unmet medical need.

  • Therapix Biosciences Spotlighted in Financial and Trade Media Outlets
    PR Newswire7 months ago

    Therapix Biosciences Spotlighted in Financial and Trade Media Outlets

    TEL AVIV, Israel , Nov. 21, 2017 /PRNewswire/ --Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on ...

  • PR Newswire7 months ago

    Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

    TEL AVIV, Israel, Nov. 10, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based treatments, executed a non-exclusive material transfer agreement with Yissum, the technology transfer company of The Hebrew University of Jerusalem, for two synthetic cannabinoids synthesized by Raphael Mechoulam, Ph.D., Professor of medicinal chemistry at the university and Chairman of the Therapix Scientific Advisory Board. Therapix plans to initiate a preclinical study during the fourth quarter to evaluate the opioid-sparing effect of these compounds in a rat model.

  • Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update
    PR Newswire7 months ago

    Therapix Biosciences Reports Third Quarter 2017 Financial Results and Provides Business Update

    - Conference Call and Webcast Today at 8:30 a.m. EDT / 5:30 a.m. PDT - TEL AVIV, Israel , Nov. 9, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical ...

  • Therapix to Present at and Attend Investor Conferences in London
    PR Newswire7 months ago

    Therapix to Present at and Attend Investor Conferences in London

    Presentation at the Biotech & Money Inv€$tival Showcase to Be Held on November 14, 2017 at 4:15PM CET TEL AVIV, Israel , Nov. 7, 2017 /PRNewswire/ -- Josh Blacher, Chief Financial Officer of Therapix Biosciences ...

  • Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017
    PR Newswire8 months ago

    Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017

    TEL AVIV, Israel , Nov. 2, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, announced ...

  • Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer
    PR Newswire8 months ago

    Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer

    TEL AVIV, Israel, Nov. 2, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty clinical-stage pharmaceutical company developing cannabinoid-based treatments, has appointed Ascher Shmulewitz, M.D., Ph.D., the Company's Chairman of the Board of Directors, to the role of Interim Chief Executive Officer (CEO), effective immediately. The Company's Board of Directors and Audit Committee, as confirmed by yesterday's shareholder approval at its annual general meeting of shareholders, determined that authorizing Dr. Shmulewitz to serve as Interim CEO is currently the most effective leadership structure.

  • CNW Group8 months ago

    Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd

    Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd

  • PR Newswire8 months ago

    Live Investor Conference & Webinar: NASDAQ, NYSE and OTC companies present November 2nd

    Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , Oct. 30, 2017 /PRNewswire/ -- PR Newswire and BetterInvesting (NAIC) today announced the agenda for the ...

  • Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea
    PR Newswire8 months ago

    Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea

    TEL AVIV, Israel, October 18, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, signed an agreement with Assuta Medical Center, the largest hospital network and private healthcare provider in Israel, to conduct a Phase IIa, sponsor-initiated trial (the "OSA Trial") for the treatment of Obstructive Sleep Apnea ("OSA") using the Company's proprietary cannabinoid-based technology, THX-OSA01.